The legality of fixing genetic disorders in embryos
To further public understanding of regenerative medicine, EuroStemCell has published lay summaries for all articles from the latest Regenerative Medicine special focus issue.
EuroStemCell have launched a digital platform to accompany the publication of the Regenerative Medicine two-part Special Focus Issue entitled “Regenerative Medicine in Society: Interdisciplinary Perspectives”. The platform presents lay summaries of each article in the issue which are freely available to all in order to engage and educate non-experts on the key issues surrounding regenerative medicine.
You can now read the lay summary for the article entitled, “Legal issues regarding gene editing at the beginning of life: an EU perspective” from Iñigo De Miguel Beriain .
DNA editing methods have advanced to the point that they could be used on human embryos to correct gene mutations that cause numerous diseases at the earliest stages of life. While there are ethical issues to address about such technology, the legality of this is not often discussed. Current laws and regulations are examined to understand the current legality of editing the DNA of embryos for medical purposes for Europe and its member states.
What questions & challenges are raised? What insight and direction does this give for research policies? To find out, read the full lay summary on the EuroStemCell website here: https://www.eurostemcell.org/regenerative-medicine-society/legality-fixing-genetic-disorders-embryos
The full original article can be accessed here: https://www.futuremedicine.com/doi/10.2217/rme-2017-0033
 De Miguel Beriain I. Ethical and legal issues regarding gene editing at the beginning of life: an EU perspective. Regen. Med. 12(6), 669–679 (2017).